Otezla Reduces Oral Ulcers in Japanese Behcet’s Disease Patients in PIII Study: Celgene

The Japan arm of Celgene announced on December 19 that its oral phosphodiesterase 4 (PDE4) inhibitor Otezla (apremilast) reduced oral ulcers in a PIII trial in Japanese patients with active Behcet’s disease. According to analysis data on the Japanese patient...read more